1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Morishita Jintan Co., Ltd.

Morishita Jintan Co., Ltd.

TTSE:4524
2,209.00
JPY
-9.00
(-0.41%)
9.12BMarket Cap
Nov 11Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
2,539.82
2,408.69
2,561.2
2,668.14
2,683.3
2,485.12
2,403.44
2,314.51
2,345.6
2,783.28
3,037.71
3,122.03
3,102.7
- -
Basic EPS, GAAP
89.95
24.33
92.17
59
96.88
86.3
79.12
50.58
69.41
120.31
170.67
133.77
153.57
- -
Free Cash Flow per Basic Share
58.99
193.68
142.81
255.41
34.42
85.57
75.92
69.73
-39
175.2
-111.41
-2.45
-18.83
- -
Dividend per Share
37.36
37.36
14.99
37.36
37.37
49.91
37.35
37.32
37.28
37.24
39.91
49.89
54.78
- -
Book Value per Share
2,066.69
2,116.45
2,245.26
2,282.24
2,409.08
2,401.99
2,459.29
2,520.85
2,563.05
2,790.38
2,971.99
2,970.46
3,165.85
- -
Tangible Book Value per Share
1,985.59
2,054.76
2,192.16
2,232.58
2,370.23
2,335.37
2,381.43
2,425.39
2,450.76
2,703.91
2,903.95
2,905.69
3,093.87
- -
Basic Weighted Avg Shares
4
4
4
4
4
4
4
4
4
4
4
4
4
4
Sales/Revenue/Turnover
10,334
9,800
10,420
10,854
10,913
10,107
9,782
9,427
9,563
11,359
12,406
12,766
12,688
- -
Operating Margin (%)
9.58
7.44
9.75
3.96
5.04
4.2
4.68
2.43
3.18
5.05
5.8
6.34
5.49
- -
Depreciation Expense
668
705
718
708
616
602
787
590
585
627
576
578
596
- -
Net Income, GAAP
366
99
375
240
394
351
322
206
283
491
697
547
628
- -
Effective Tax Rate (%)
7.09
19.51
- -
36.41
25.52
21.6
30
17.86
26.23
21.03
15
29.15
18.63
- -
Profit Margin (%)
3.54
1.01
3.6
2.21
3.61
3.47
3.29
2.19
2.96
4.32
5.62
4.28
4.95
- -
Working Capital
2,149
2,096
2,381
3,095
2,973
3,372
3,945
4,037
4,128
4,327
3,827
5,351
5,196
- -
LT Debt
1,577
1,197
867
875
757
860
821
749
469
242
106
1,298
1,405
- -
Total Equity
8,409
8,611
9,134
9,284
9,799
9,770
10,012
10,272
10,454
11,391
12,143
12,152
12,976
- -
Return on Invested Capital (%)
3.44
0.85
- -
2.52
3.68
2.96
2.82
1.6
1.93
3.84
4.89
4.32
3.94
- -
Return on Capital (%)
3.81
1.12
- -
2.32
3.69
3.27
2.95
1.87
2.53
4.25
5.7
4.22
4.55
- -
Return on Common Equity (%)
4.45
1.16
4.23
2.61
4.13
3.59
3.26
2.03
2.73
4.5
5.92
4.5
5
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
76
429
- -
LT Borrowings
1,234
1,206
- -
LT Finance Leases
- -
199
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
9,103
9,120
8,833

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
7,657
7,773
- -
Cash, Cash Equivalents & STI
1,061
1,828
- -
Accounts Receivable, Net
2,792
2,256
- -
Inventories
3,221
3,306
- -
Total Current Liabilities
2,592
2,577
- -
Payables & Accruals
- -
- -
- -
ST Debt
76
429
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.61%
4.84%
6.78%
Free Cash Flow
-17.56%
-59.42%
670%
Net Income, GAAP
11.91%
29.23%
14.81%
Sales/Revenue/Turnover
2.22%
6.35%
-0.61%
Total Cash Common Dividend
- -
- -
9.8%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
12,766
2026
- -
- -
- -
- -
12,688
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
133.77
2026
- -
- -
- -
- -
153.57
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
49.89
2026
- -
- -
- -
- -
54.78
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yuji Morishita
Full Time Employees
359
Sector
Health technology
Industry
Pharmaceuticals: other
Address
1-2-40, Tamatsukuri Osaka OS Japan 540-8566
IPO Date
Oct 2, 1961
Website
jintan.co.jp
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Morishita Jintan Co., Ltd. operates primarily in the pharmaceutical and health supplement industries, manufacturing and selling pharmaceutical products, functional foods, dietary supplements, and contract manufacturing of seamless capsules. Its product portfolio includes probiotic supplements under the "Bifina" brand, collagen beauty drinks, health and gut-focused products such as the "CHO-TECH" series, and various functional food items including nuts, fruits, and mint candies for nose and throat care. The company also engages in the development and manufacturing of quasi-drugs and medical devices, supporting health and wellness through traditional and innovative preventive healthcare solutions. Morishita Jintan targets consumer health markets primarily in Japan, with growing operations in Asian countries including China, Hong Kong, and Vietnam. Founded in 1893, the company is headquartered in Osaka, Japan. Recently, Morishita Jintan has made strategic expansions including the acquisition agreement to acquire MJ Shiga Co., Ltd. from Wada Calcium Pharmaceutical Co., Ltd. announced in 2023, expected to finalize by December 2023. It has launched new products such as the "Jintan Collagen EXCELL PUMP" beauty drink in Hong Kong, expanded its "Nose & Throat Mint Candy" with new variants, and introduced a new combination OTC product "Prebalance" featuring acacia dietary fiber and fructo-oligosaccharides. The company has also strengthened its environmental commitment by establishing the Morishita Jintan Group Environmental Policy focused on sustainability. Additionally, it is innovating capsule technology through partnerships, including with L'Oreal Japan for active delivery capsules containing cosmetic ingredients. Morishita Jintan actively promotes health information through initiatives like the "CHO-TECH" website and pursues diversification into inedible fields using its capsule technology. The company operates across Japan and other Asian markets, leveraging its extensive experience to combine traditional oriental medicine concepts with modern technology. Morishita Jintan employs around 350 people and reports consolidated sales primarily from its solution planning and consumer business segments. Its ongoing product development, acquisitions, and strategic alliances reflect a comprehensive approach to expanding health-related offerings domestically and internationally while integrating sustainability into its corporate strategy. This description reflects the company's core products, recent strategic developments, industry focus, and geographic reach as of late 2025.